NEW YORK, May 9 (Reuters) - The Chief Executive Officer of Kos Pharmaceuticals Inc. (KOSP.O: Quote, Profile, Research) on Tuesday said a rival cholesterol drug being developed by Merck & Co. could have a number of disadvantages, including safety issues likely to arouse scrutiny of U.S. regulators.
